Therapy resistance on the RADar in ovarian cancer.

Jonas Schwickert Franziska Maria Zickgraf Martin R Sprick

Published in: EMBO molecular medicine (2021)

Ovarian cancer has the worst prognosis of all gynecological cancers with high-grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high-grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021).

Keyphrases

high grade
end stage renal disease
low grade
ejection fraction
newly diagnosed
peritoneal dialysis
poor prognosis
dna damage
oxidative stress
binding protein
replacement therapy